Helixmith헬릭스미스

Helixmith's trailing revenue is small against large operating losses, though the shares have rebounded over the past month.

Helixmith is a Korean R&D-focused biotech with plasmid DNA and gene therapy platform services, plus B2B health food and cosmetics sales. Over the trailing twelve months to H1 2026 it reported about ₩2.4B of revenue, an operating loss of about ₩9.4B and a net loss of about ₩1.6B. The latest headline points to the first commercial shipment of 'Hwasuo Ling' by partner Nordland, with royalty inflows expected to begin.

What stands out

• Trailing revenue of about ₩2.4B against an operating loss of about ₩9.4B gives an operating margin of roughly -390%.
• Revenue fell about 48% in 2025 to ₩2.6B, after growing in 2024, and losses have narrowed sharply from 2022-2023 levels.
• Net loss in the trailing period was about ₩1.6B, much smaller than the ₩64B loss in 2023 and ₩15.5B in 2024.
• The balance sheet shows cash of about ₩8.2B and borrowings of about ₩1.2B, with liabilities at 1.1% of equity; free cash flow over the trailing period was negative at about -₩7.3B.
• Shares closed at ₩3,810, up 27% over one month but down 28% over one year, and trade well below the 52-week high of ₩9,960. Foreign ownership fell from 3.9% to 2.5% over 60 days.

What to watch

• The timing and size of royalty inflows from the Nordland launch of Hwasuo Ling, which the data does not quantify.
• Cash burn: trailing free cash flow of about -₩7.3B against cash of about ₩8.2B, with no forecast available in the data.
• Upcoming quarterly and annual filings, and any new shareholder or holding disclosures, since the data contains no analyst estimates or guidance.